Chemotherapy as a regulator of extracellular matrix-cell communication: Implications in therapy resistance

The development of most solid cancers, including pancreatic, breast, lung, liver, and ovarian cancer, involves a desmoplastic reaction: a process of major remodeling of the extracellular matrix (ECM) affecting the ECM composition, mechanics, and microarchitecture. These properties of the ECM influen...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 2022-11, Vol.86 (Pt 3), p.224-236
Main Authors: Gonzalez-Molina, Jordi, Moyano-Galceran, Lidia, Single, Andrew, Gultekin, Okan, Alsalhi, Shno, Lehti, Kaisa
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cancer
Cell Communication
Chemoresistance
Chemotherapy
ECM
Extracellular Matrix
Humans
Medicin och hälsovetenskap
Neoplasms - drug therapy
Plasticity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of most solid cancers, including pancreatic, breast, lung, liver, and ovarian cancer, involves a desmoplastic reaction: a process of major remodeling of the extracellular matrix (ECM) affecting the ECM composition, mechanics, and microarchitecture. These properties of the ECM influence key cancer cell functions, including treatment resistance. Furthermore, emerging data show that various chemotherapeutic treatments lead to alterations in ECM features and ECM-cell communication. Here, we summarize the current knowledge around the effects of chemotherapy on both the ECM remodeling and ECM-cell signaling and discuss the implications of these alterations on distinct mechanisms of chemoresistance. Additionally, we provide an overview of current therapeutic strategies and ongoing clinical trials utilizing anti-cancer drugs to target the ECM-cell communication and explore the future challenges of these strategies.
ISSN:1044-579X
1096-3650
1096-3650
DOI:10.1016/j.semcancer.2022.03.012